265 related articles for article (PubMed ID: 9452347)
1. Selegiline, pregnancy, and Parkinson's disease.
Kupsch A; Oertel WH
Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
[No Abstract] [Full Text] [Related]
2. Selegiline for Parkinson's disease.
Calesnick B
Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
4. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
5. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
Schneider E
J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease.
Imke S
Adv Nurse Pract; 1998 Jan; 6(1):24-8. PubMed ID: 9495941
[No Abstract] [Full Text] [Related]
7. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
8. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Jost WH; Friede M; Schnitker J
Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607
[No Abstract] [Full Text] [Related]
10. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
11. MAO-B inhibitor know-how: back to the pharm.
Lewitt PA
Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
[No Abstract] [Full Text] [Related]
12. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
13. [Use of iumeks in the combined therapy of parkinsonism patients ].
Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA
Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
[No Abstract] [Full Text] [Related]
14. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
16. The fabulous neuroprotection of selegiline: memoir and prospectus.
Landau WM
J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135
[No Abstract] [Full Text] [Related]
17. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Marconi S; Zwingers T
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
[TBL] [Abstract][Full Text] [Related]
18. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
[TBL] [Abstract][Full Text] [Related]
19. [Neuroprotective and neurorestorative therapy in Parkinson's disease].
Jiménez-Jiménez FJ; Molina JA
Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687
[TBL] [Abstract][Full Text] [Related]
20. [What strategies are recommended for early stage disease? Other treatments].
Damier P
Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
